Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Ann Rheum Dis.

Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T

doi: 10.1136/annrheumdis-2020-217139.

COMMENTED

Immunotherapy

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

★ 3 Recommended and commented by Prof. Dr Dr Sacha Rothschild, Faculty Member

Eur J Cancer

Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O

doi: 10.1016/j.ejca.2021.03.010

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

T Cells

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer

J Autoimmun

Calabrese LH, Caporali R, Blank CU, Kirk AD

doi: 10.1016/j.jaut.2020.102546

Melanoma and Skin Cancer

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Melanoma Res

Lauwyck J, Beckwée A, Santens A, Schwarze JK, Awada G, Vandersleyen V, Aspeslagh S, Neyns B

doi: 10.1097/CMR.0000000000000748

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Immunotherapy

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

Eur J Cancer

Makarious D, Horwood K, Coward JIG

doi: 10.1016/j.ejca.2017.05.041.

Autoimmune DiseaseImmunotherapy

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

Arthritis Rheumatol.

Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M, Groupe de Cancérologie Cutanée (GCC), Groupe Français de Pneumo-Cancérologie (GFPC), Club Rhumatismes et Inflammations (CRI).

doi: 10.1002/art.41068.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Rheumatological complications of immune checkpoint inhibitor therapy

Rev Med Suisse.

Lazarou I, Fernandez E

doi: undefined.

Related content